Has Nada Hamzy received payments from drug or device companies?

Yes. Drug and device makers reported $1,515 in general payments to Nada Hamzy across 92 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nada Hamzy did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nada Hamzy come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nada Hamzy

Pediatrics · Columbia, SCNPI 1740397918

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $398 and has fallen 90.1% since, to $39 in 2024.

$1,515in general payments, 2019–2025

Across 92 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Ironshore Pharmaceuticals Inc.$292
Tris Pharma Inc$223
Adlon Therapeutics L.p.$200
Pfizer$111
Cranial Technologies, Inc$107
Corium, LLC$92
plus $491 from 15 others

What the payments were for

Food & beverage$1,515100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Ironshore Pharmaceuticals Inc.	13	$292
Tris Pharma Inc	13	$223
Adlon Therapeutics L.p.	12	$200
Pfizer	8	$111
Cranial Technologies, Inc	7	$107
Corium, LLC	6	$92
Takeda Pharmaceuticals U.S.A., Inc.	6	$89
GSK	6	$83
Seqirus USA Inc	4	$64
AstraZeneca	2	$39
Genentech USA, Inc.	2	$31
Supernus Pharmaceuticals, Inc.	2	$28
Merck	2	$25
Sanofi Pasteur Inc.	2	$24
Ultragenyx Pharmaceutical Inc.	1	$21
Aytu Biopharma, Inc.	1	$20
Novo Nordisk	1	$17
Vertical Pharmaceuticals, LLC	1	$14
Kaleo, Inc.	1	$12
Shire North American Group Inc	1	$12
Neos Therapeutics, LP	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Jornay PM 20mg capsules (Bottle of 100)$139

How this compares

$1,515 in reported general payments places this provider in the 85th percentile of 969 pediatrics providers in South Carolina.

See all pediatrics providers in South Carolina →

Other pediatrics in Columbia

Cara O NeillColumbia$12K
John CarrollColumbia$7K
Laura AlbergColumbia$6K
Richard ShroudsColumbia$5K
Kelly BranstetterColumbia$3K
Jennifer SoroosColumbia$3K
Emily SandersColumbia$3K
Elizabeth HaileColumbia$3K
Deborah GreenhouseColumbia$2K
Theodore DuboseColumbia$2K

See the full list for South Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →